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Abstract: 
We present here a combined GC–MS and LC–MS metabolic profiling approach to unraveling 
the pathological outcomes of aristolochic acid (AA)-induced nephrotoxicity. Urine samples were 
analyzed by GC–MS and LC–MS in combination with pattern recognition techniques, e.g. 
principal component analysis (PCA), orthogonal projection to latent structure-discriminant 
analysis. The work indicates that AA-induced acute renal toxicity as evidenced by 
histopathological examinations could be characterized by systemic disturbance of metabolic 
network involving free fatty acids generation, energy and amino acids metabolism, and alteration 
in the structure of gut microbiota. Therefore, this method is potentially applicable to the 
toxicological study, providing a comprehensive understanding of systems response to xenobiotic 
intervention. 
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Article: 
1. Introduction 
Aristolochic acid (AA), widely present in the botanicals, i.e. Aristolochia, Bragantia and Asarum 
species, is generally believed to cause acute renal failure (ARF), characterized by interstitial 
fibrosis, hyperproteinemia, severe anaemia, and uremia [1], [2], [3] and [4]. Conventional 
toxicological studies on AA focused merely on nephrotoxic mechanisms such as the activation or 
inhibition of certain enzymes related to the renal lesion [5], [6], [7], [8] and [9]. Recently, the 
revival of systems biology aiming to integrate all the pertinent components, e.g. genes, proteins, 
and metabolites, and all intricate relationship into a holistic biological network provides 
comprehensive thoughts in understanding and addressing systems‟ behavior [10] and [11]. 
 
Metabolomics/metabonomics, concomitant with genomics, metagenomics, proteomics, etc., is a 
newly thriving systems biology and has been highly favored in botanical science [12], 
environmental research [13], and toxicological study in preclinical and clinical fields [14], [15], 
[16] and [17]. The goal of global metabolic profiling is to monitor as many metabolites with low 
molecular weight as possible in a single cell, biofluids, and tissue extracts [18]. However, none 
of the analytical instruments including NMR, GC–MS, LC–MS, and CE-MS has so far been able 
to capture the entire composition of endogenous metabolites. The use of multiple analytical 
methods in combination may offer a better strategy for identifying a broadened spectrum of 
important metabolites associated with physiological and/or pathological variations [19], [20] and 
[21]. 
 
It is technically challenging to integrate data from different analytical methods which measure 
different types of biochemical molecules generated from diverse aspects of a system, during 
which repercussions resulting from systematic biases, false-positive or -negative rates inherent in 
the high-throughput assays are to be under scrutiny [10] and [22]. To date, enormous efforts have 
been made to integrate a variety of data from multiple analytical platforms, which have 
facilitated the identification of subtle variation between two physiological states using simplified 
mathematical models [11], [22] and [23]. 
 
We have previously established a time-dependent changing metabonomic profile in AA-induced 
nephrotoxic model using HPLC-ESI-MS [24]. In this work, we repeated the previous study using 
GC–MS analytical technique, in which we have identified a number of important metabolites 
related to AA toxicity. Multivariate statistical analysis was used to process the integrated dataset 
generated from LC–MS and GC–MS, allowing a comprehensive understanding of mechanisms 
of AA-induced nephrotoxicity. 
 
2. Materials and methods 
2.1. Animal handling and sampling 
The study was approved by China national legislation and local guidelines. The experimental 
protocols followed our previously published work [24]. Urine samples were collected at different 
time-points from the male Wistar rats dosed with AA or vehicle, and immediately kept at −70 °C 
until MS measurement. 
 
2.2. GC–MS spectroscopy acquisition 
Each 300-μL aliquot of urine sample was mixed with 300 μL of water for ethyl chloroformate 
(ECF)-derivatization prior to GC–MS spectral acquisition as described[25]. One microlitre of the 
analyte was injected into a DB-5MS capillary column coated with 5% diphenyl cross-linked 95% 
dimethylpolysiloxane (30 m × 250 μm i.d., 0.25 μm film thickness; Agilent J&W Scientific, 
Folsom, CA) performed on a hyphenated analytical technique, gas chromatography–mass 
spectrometry (Perkin–Elmer Inc., USA). 
 
2.3. LC–MS spectroscopy acquisition 
Details of the protocol were provided in our previously published paper [24]. 
 
2.4. Preprocessing of data 
The data from the GC–MS and LC–MS analysis were converted to NetCDF format via 
DataBridge (Perkin–Elmer Inc.) and Agilent LC/MSD ChemStation (Rev.B.01.03, Agilent 
Tech., USA), respectively. Each file was extracted subsequently using our custom scripts in the 
MATLAB 7.0 (The MathWorks, Inc., USA), where baseline correction, and peak resolving and 
alignment were carried out. The output data were organized in the form of arbitrary peak index 
(retention time–m/z pair), sample names (observations), and peak intensity information 
(variables). 
 
Directly concatenating the matrices of processed-MS data is sub-optimal as this may result in a 
matrix with an unfavorable samples-to-variables ratio [22]. It is necessary to use properly 
reduced matrix to conduct multivariate statistical analysis. Notably, GC–MS data inherently 
contain apparent variability and complexity such as multiple fragments from a single compound. 
A simple strategy was to combine these fragments with the same retention time into a single 
compound. The binning procedure should be manually confirmed by comparing the major ion 
fragments of a compound detected with those from commercially available and in-house libraries 
in order to minimize the prejudice to confounding peaks. Using previously established GC–MS 
analysis protocol, we detected about 200–250 different urine metabolites, with 87 of them 
identified by means of the library or verified via authentic standards. Lacking the effective peak 
resolving method for LC–MS data, we used an optimized voltage, which is kept stable and 
constant throughout the experiment, to obtain a number of the corresponding molecular ions 
[M+H+] deriving from endogenous metabolites. Ultimately, an integrated matrix was obtained 
for subsequent multivariate statistical analysis by merging the two sets of data. 
 
Since MS-data were obtained from different analytical instruments and urine volume varied over 
subjects, block normalization to the total sum of the chromatogram was conducted on GC–MS 
and LC–MS data, respectively. The internal standard for on-line supervising inter-batch 
reproducibility and for automated peak matching algorithm of retention time was removed prior 
to the normalization. Mean-centering was performed columnwise to remove the offsets and 
autoscaling (scaled to unit variance) to put all the measured metabolites on an equal level. That 
is, metabolites present at low concentrations are of equal importance with those present at high 
concentrations. 
 
2.5. Multivariate statistical analysis 
GC–MS and LC–MS data of urine samples from the two groups (AA-induced nephrotoxicity 
group versus the healthy control) at the 7th day postdose were analyzed by principal component 
analysis (PCA) to envisage the perturbation of the metabolic network of the AA-treated animals. 
Orthogonal projection to latent structure-discriminant analysis (OPLSDA) was carried out on the 
integrated MS data allowing the identification of differential metabolites in the urine. In the 
OPLSDA algorithm, the variation in X (the combined MS data) is decomposed into three parts: 
the first being the variation in X related to Y (the class variable, e.g., 0/1), and the last two 
containing the specific systemic variation in X and residual, respectively. This leads to a model 
with a minimal number of predictive components defined by the number of degrees of freedom 
(k − 1 dimensions) between group variances (k classes). Therefore, the interpretation of 
differential metabolites in the two groups is straightforward using one loading alone. To validate 
the model against over-fitting, the prediction accuracy (cross-validation parameter) was 
computed. Details regarding OPLSDA algorithm are available in other publications [26]. 
 
3. Results 
3.1. PCA of integrated MS matrix 
The scores plot (PC1 versus PC2) derived from the integrated MS-data (Fig. 1) depicted two 
distinct clustering without any overlap between the groups (AA-treated group and the healthy 
control). The separation of the two groups occurred in the PC1, and the cluster appeared to be 
tighter in the healthy control group as compared to the AA-dosed group. These findings were in 
good agreement with LC–MS-based metabolic profiles as well as the histopathological 
examination [24]. 
 
 
Fig. 1. PCA scores plot (PCI versus PC2) derived from the integrated MS data of urine samples 
obtained from AA-induced nephrotoxicity rats ( ) and the healthy control ( ). Hotelling T2 
ellipse = 95% confidence limit. 
 
3.2. Investigation of the differential metabolites by OPLSDA 
OPLSDA model was generated with one predictive component, and one orthogonal component 
to discriminate the two group rats. R2X and R2Y represented the fraction of the variation of all the 
X variables (the combined MS data) and the “dummy” Y variables (0/1) by the model, 
respectively. The R2Y values in this work (approximately 1.0) suggested a satisfactory model 
(Fig. 2a). The prediction accuracy (Q2Y > 0.75) obtained through a typical 7-fold cross-validation 
further guaranteed the models (Fig. 2a). Additionally, the distance to model is calculated for each 
sample using the integrated MS data (a critical value of 99.5% for outliers marked as a dashed 
line) in case of spurious effects of outlying samples (Fig. 2b). However, no outlying data point 
was observed at this threshold, meaning that any metabolite of interest mirrored the general 
effects after exposure to AA. The correlation coefficients (r > 0.70 was considered as having 
good discriminant ability) resulting from OPLSDA of the integrated MS data were summarized 
in Table 1, where the metabolites were designated according to the corresponding GC–MS and 
LC–MS analyses. The reduced urinary excretion levels of citrate, aconinate, isocitrate, succinate, 
m-hydroxyphenylpropionate, caprylic acid, valeric acid, arachidonic acid, methionine, and 
elevated levels of serine, p-cresol, p-hydroxyphenylacetate, cystine, cysteine, and homocysteine 
were detected in the AA-dosed rats as compared to the healthy controls. These metabolites were 
identified by authentic standards available (Sigma–Aldrich, USA) and the commercial 
compound libraries: NIST, Wiley in Turbomass 4.1.1 software (Perkin–Elmer Inc.). No overlap 
in analytical outcomes was observed between the two methods probably due to the difference 
between the GC–MS and LC–MS techniques. 
 
 
Fig. 2. (a) OPLSDA model summary of the combined MS dataset. For more explanation of the 
R
2
X, R2Y, and Q2Y values, see the text. (b) The distance to model plot. (•, sample values). 
 
Table 1.  
A list of most profound metabolites relevant to the AA-induced nephrotoxicity 
Metabolites (GC–MS) 
Correlation 
coefficients
a
 
Metabolites (LC–
MS) 
Correlation 
coefficients
a
 
Citrate −0.83 (↓) Caprylic acid −0.84 (↓) 
Aconitate −0.76 (↓) Valeric acid −0.92 (↓) 
Isocitrate −0.91 (↓) Arachidonic acid −0.79 (↓) 
Succinate −0.79 (↓) Methionine −0.81 (↓) 
m-
Hydroxyphenylpropionate −0.74 (↓) Serine 0.92 (↑) 
p-Cresol 0.84 (↑) Homocysteine 0.78 (↑) 
p-Hydroxyphenylacetate 0.79 (↑)   
Metabolites (GC–MS) 
Correlation 
coefficients
a
 
Metabolites (LC–
MS) 
Correlation 
coefficients
a
 
Cystine 0.81 (↑)   
Cysteine 0.92 (↑)   
a The correlation coefficients shown are based on the OPLSDA of the integrated MS dataset, 
positive value indicates an increase of the metabolites in the AA-dosed group (denoted by an up-
arrow), whereas negative value represents a decreased level of the metabolites in this group.  
 
4. Discussion 
In this study, we have verified the previous research results using a different analytical method. 
Based on the integrated MS matrix, we have adopted OPLSDA to identify the perturbed 
metabolic pathways relating to AA-induced nephrotoxicity. The work suggested that the 
application of different analytical methods may capture different sets of endogenous metabolites 
with unique biological significance, and that integration of dataset from multi-analytical 
platforms is technically feasible and of great significance for a comprehensive understanding of 
systemic perturbation. 
 
Metabolic disorder of amino acids, homocysteine and serine in particular, is commonly used as 
the criteria for diagnosis of kidney morbidity [5], [6], [7], [8] and [9]. In this study, such 
disturbed amino acids as cystine, cysteine, homocysteine, methionine, and serine identified in the 
urine probably reflected the impaired renal tubule and subsequent cellular interstitial fibrosis due 
predominately to the direct cytotoxic effects of AA on kidney [27]. In addition, the significant 
variations of homocysteine and methionine were detected by LC–MS analysis, whereas changes 
in cystine and cysteine concentration were observed by GC–MS analysis. Combining the results 
obtained from two analytical methods together, a disturbed metabolic pathway emerged (Fig. 3a) 
[28], benefiting from the use of two complementary methods. 
 
 
Fig. 3. The perturbed metabolic pathways in response to AA exposure: (a) AA-induced 
metabolic disorder of amino acids; (b) AA perturbed TCA cycle; (c) PLA2-related mechanisms 
of AA-induced nephrotoxicity. Dark square denotes an elevated concentration of metabolites 
present in the urine from rats exposed to AA, whereas gray square means a reduced level of 
metabolites in this group as compared to the healthy. 
 
The negative OPLSDA correlation coefficients of the fatty acids such as caprylic acid, valeric 
acid and arachidonic acid, indicated the declined levels of these metabolites in the AA-dosed 
group as compared to the healthy control. Arachidonic acid, an intermediate in the production of 
prostaglandins (PGs), is produced during the process of phospholipids hydrolyzation by means 
of phospholipase A2 (PLA2) into lecithin and phosphatidylinostitol. Phospholipase A2 (PLA2) is 
greatly inhibited by AA, leading to a reduced level of arachidonic acid (Fig. 3b) [28], [29], [30], 
[31] and [32]. The down-regulated production of arachidonic acid may negatively impact the 
production of PGs which play important roles in renal functions, e.g. attenuating renal 
vasodilatation, regulating renal circulation, and affecting renal sodium excretion and water 
reabsorption, ultimately leading to kidney lesion [33]. It is therefore assumed that depletion of 
arachidonic acid may be one of the fundamental causes of acute renal failure induced by AA. 
 
GC–MS analytical method was able to identify the significant variations of phenyl-containing 
compounds such as p-cresol, p-hydroxyphenylacetate, and m-hydroxyphenylpropionate. These 
compounds are manipulated mainly by gut microbiota in the living systems through fermentation 
of dietary polyphenols and aromatic amino acids [34]. The variations in phenyl-containing 
metabolites suggested that the gut microbiota was greatly restructured by the AA intervention. 
The principal metabolites of AA are aristolactam I, aristolactam Ia, and aristolactam II that are 
produced through classical bacterial nitroreductase, and these aristolactams are the precursors of 
AA–DNA adducts responsible for triggering or accelerating a fibrotic process [35], [36], [37] 
and [38]. In this context, the significant disorders of symbiotic bacteria may be indicative of AA-
induced acute kidney lesion. 
 
It has been well documented that citrate, aconite, iso-citrate and succinate are the crucial 
substances of tricarboxylic acids (TCA) cycle (Fig. 3c) [28], which is the main pathway of 
glucose degradation and is primary energy supplier for universal organisms. Following the 
nephrotoxicity induced by AA, these compounds were significantly decreased when compared 
with the healthy control animals, suggesting that AA may inhibit the activity of these 
compounds, ultimately repressing energy metabolism [39] and [40]. This finding was consistent 
with the experimental observations on AA-treated rats with much reduced daily activity and a 
tendency to press close together. 
 
The combined use of multiple analytical instruments, such as GC–MS and LC–MS, takes 
advantage of complementary outcomes and therefore, provides an improved analytical means for 
explaining the biological variation in the living systems. Our study using the combined MS-
based metabolic profiling technique has revealed that AA led to direct cytotoxic effect and 
enzyme inhibition, and to the significant alteration of gut-motivated metabolites and energy 
metabolism, ultimately leading to a disruption of the kidney-related metabolic regulatory 
network and renal function. 
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